Neulasta Pharmacology Quiz

Questions and Answers

What is Neulasta® indicated for?

To decrease the incidence of infection, as manifested by febrile neutropenia (correct)

For the mobilization of peripheral blood progenitor cells

To treat non-myeloid malignancies (correct)

For patients receiving myelosuppressive anti-cancer drugs (correct)

Which of the following is/are true about Neulasta® dosing and administration? (Select all that apply)

Do not administer Neulasta® between 14 days before and 24 hours after chemotherapy (correct)

Administer a single subcutaneous injection of 6 mg (correct)

Administer Neulasta® 14 days before chemotherapy

Neulasta® is administered subcutaneously (correct)

How is Neulasta supplied? (Select all that apply)

Single-dose vials for intravenous use

Supplied with a 10-gauge needle

Prefilled single-dose syringe containing 6 mg pegfilgrastim (correct)

Prefilled syringe with 27-gauge needle (correct)

A healthcare provider must fill the on-body injector for Neulasta® using the prefilled syringe.

True Signup and view all the answers

Approximately _ hours after the OBI for Neulasta® is applied, Neulasta® will be delivered over approximately _ minutes.

27; 45 Signup and view all the answers

Please select the TRUE statements regarding Neulasta®.

A missed dose should be given by single prefilled syringe for manual use Signup and view all the answers

Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.

True Signup and view all the answers

What are the Warnings and Precautions for Neulasta®?

Splenic rupture, Acute Respiratory Distress Syndrome, Serious Allergic Reactions, Allergies to Acrylics, Sickle Cell Disorders, Glomerulonephritis, Leukocytosis, Capillary Leak Syndrome, Potential for Tumor Growth Stimulatory Effect, Potential Device Failures. Signup and view all the answers

What are the most common adverse reactions occurring in >5% of patients in pegfilgrastim trials?

Bone pain and pain in extremity. Signup and view all the answers

Which statements regarding the use of Neulasta® in pregnant women are true?

Pregnancy registry exists for women treated with Neulasta® Signup and view all the answers

No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients who received Neulasta®.

True Signup and view all the answers

In the mechanism of action of Neulasta®, pegfilgrastim is a ___ that acts on _ by binding to specific cell surface receptors, thereby stimulating _, _, _, and ___.

Colony-stimulating factor; hematopoietic cells; proliferation; differentiation; commitment; end cell Signup and view all the answers

Neutrophil receptor binding is an important component of the clearance of pegfilgrastim.

True Signup and view all the answers

What is the half-life of Neulasta® after subcutaneous injection?

15 to 80 hours. Signup and view all the answers

In Clinical Studies 1 and 2, both studies met the major efficacy outcome measure.

True Signup and view all the answers

Study Notes

Neulasta Indications and Administration

Neulasta® decreases the incidence of infection, specifically febrile neutropenia, in non-myeloid malignancy patients undergoing myelosuppressive therapies.
It is not meant for mobilizing peripheral blood progenitor cells for stem cell transplantation.
Administer a single subcutaneous injection of 6 mg once per chemotherapy cycle.
Do not administer Neulasta® between 14 days before and 24 hours after cytotoxic chemotherapy.

Neulasta Drug Supply and Usage

Supplied in a prefilled single-dose syringe containing 6 mg of pegfilgrastim and a 27-gauge, ½-inch needle with an UltraSafe® Needle Guard.
The syringe contains 0.64 mL of solution, delivering 6 mg/0.6 mL when used with the on-body injector (OBI).
The OBI will deliver Neulasta® approximately 27 hours after application for a duration of 45 minutes.
The prefilled syringe in the Neulasta® Onpro® kit is exclusively for use with the OBI.

Contraindications and Warnings

Neulasta® is contraindicated for patients with a history of severe allergic reactions to pegfilgrastim or filgrastim, including anaphylaxis.
Warnings include risks of splenic rupture, Acute Respiratory Distress Syndrome (ARDS), serious allergic reactions, and potential stimulatory effects on malignant cells.
Caution advised for use in patients with sickle cell disorders and those experiencing glomerulonephritis.

Adverse Reactions and Efficacy

The most common adverse reactions occurring in more than 5% of patients include bone pain and extremity pain.
No significant safety or effectiveness differences noted between patients aged 65 and older and younger patients receiving Neulasta®.
Neulasta® has a half-life ranging from 15 to 80 hours after subcutaneous injection.

Pregnancy and Mechanism of Action

Classified as Pregnancy Category C; benefits must justify risks during pregnancy with no well-controlled studies available.
A pregnancy registry exists for women treated with Neulasta® who become pregnant.
Mechanism of action involves pegfilgrastim acting as a colony-stimulating factor for hematopoietic cells, stimulating proliferation, differentiation, commitment, and functional activation.
Neutrophil receptor binding is a key factor in the pharmacokinetics and clearance of pegfilgrastim, with serum clearance linked to neutrophil count.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

Test your knowledge on Neulasta® and its therapeutic indications. This quiz covers essential information regarding its use in oncology, specifically related to febrile neutropenia in cancer patients. Explore the significance of Neulasta in treatment plans and its limitations.

Neulasta Pharmacology Quiz

Questions and Answers

What is Neulasta® indicated for?

Which of the following is/are true about Neulasta® dosing and administration? (Select all that apply)

How is Neulasta supplied? (Select all that apply)

A healthcare provider must fill the on-body injector for Neulasta® using the prefilled syringe.

Approximately ___ hours after the OBI for Neulasta® is applied, Neulasta® will be delivered over approximately ___ minutes.

Please select the TRUE statements regarding Neulasta®.

Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.

What are the Warnings and Precautions for Neulasta®?

What are the most common adverse reactions occurring in >5% of patients in pegfilgrastim trials?

Which statements regarding the use of Neulasta® in pregnant women are true?

No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients who received Neulasta®.

In the mechanism of action of Neulasta®, pegfilgrastim is a _____ that acts on _____ by binding to specific cell surface receptors, thereby stimulating _____, _____, _____, and _____.

Neutrophil receptor binding is an important component of the clearance of pegfilgrastim.

What is the half-life of Neulasta® after subcutaneous injection?

In Clinical Studies 1 and 2, both studies met the major efficacy outcome measure.

Study Notes

Neulasta Indications and Administration

Neulasta Drug Supply and Usage

Contraindications and Warnings

Adverse Reactions and Efficacy

Pregnancy and Mechanism of Action

Studying That Suits You

Description

Approximately _ hours after the OBI for Neulasta® is applied, Neulasta® will be delivered over approximately _ minutes.

In the mechanism of action of Neulasta®, pegfilgrastim is a ___ that acts on _ by binding to specific cell surface receptors, thereby stimulating _, _, _, and ___.